Physician profile
Yangming Cao
NPI 1558339630
$1,594.84
in general payments reported to CMS, 2019-2025
17 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $28.28 · 2021: $26.42 · 2022: $354 · 2023: $375 · 2024: $313 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $440.14 | 2020-2025 | Krystexxa, Parsabiv, Aranesp |
| Horizon Therapeutics Plc | $356.34 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $202.07 | 2022-2025 | Benlysta, Jesduvroq, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $146.42 | 2019-2024 | |
| Octapharma USA, INC. | $101.56 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $42.24 | 2022 | |
| Daiichi Sankyo INC. | $41.28 | 2023-2024 | Injectafer |
| Aurinia Pharma U.S., INC. | $40.75 | 2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $40.30 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $38.43 | 2023-2024 | Farxiga |
| Kyowa Kirin, INC. | $29.48 | 2025 | |
| Fresenius USA Marketing, INC. | $27.39 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.02 | 2019 | |
| Nxstage Medical, INC. | $19.91 | 2025 | Nxstage System One |
| Calliditas Therapeutics US INC. | $17.36 | 2023 | Tarpeyo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.69 | 2025 | Gazyva |
| Amag Pharmaceuticals, INC. | $15.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yangming Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.